Spring Bank Pharmaceuticals, Inc.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
Spring Bank Pharmaceuticals, Inc. chose not to state its revenue in its newest notice of a funding round (Nov 2016).
SEC Form D · Nov 2016
The industry group it chose in its notices: Biotechnology.
SEC Form D · Nov 2016
Products and services#
No products or services on record: no website is on record for it in an official source (its SEC filings, Wikidata).
Investors#
No investor of Spring Bank Pharmaceuticals, Inc. is named in an official source we use. Its funding notices give only how many investors bought, not who they are.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Jonathan Freve | Executive officer | Nov 2016 |
| Martin Driscoll | Executive officer | Nov 2016 |
| Nezam Afdhal | Executive officer | Nov 2016 |
| Douglas John Jensen | Executive officer | Feb 2015 |
| Radhakrishnan Parameswaran Iyer | Executive officer | Feb 2015 |
| David Kris Arkowitz | Director | Nov 2016 |
| Jonathan Kris Bates | Director | Nov 2016 |
| Kurt M. Eichler | Director | Nov 2016 |
| Martin Driscoll | Director | Nov 2016 |
| R.P. Kris Iyer | Director | Nov 2016 |
| David Ellsworth Arkowitz | Director | Feb 2015 |
| Douglas John Jensen | Director | Feb 2015 |
| Guy Parameswaran Macdonald | Director | Feb 2015 |
| Jonathan Ellsworth Bates | Director | Feb 2015 |
| Radhakrishnan Parameswaran Iyer | Director | Feb 2015 |